{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Biotechnology and Bioengineering", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Amgen Inc", "name": "organizations", "rank": "5", "is_major": "Y"}, {"value": "AbbVie Inc", "name": "organizations", "rank": "6", "is_major": "Y"}, {"value": "Patient Protection and Affordable Care Act (2010)", "name": "subject", "rank": "7", "is_major": "Y"}, {"value": "Health Insurance and Managed Care", "name": "subject", "rank": "8", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbWide.jpg", "legacy": {"wide": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg", "legacy": {"xlarge": "images/2016/07/16/business/16DRUG-1/16DRUG-1-articleLarge.jpg", "xlargeheight": "851", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 851}, {"url": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/07/16/business/16DRUG-1/16DRUG-1-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1057", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow.", "pub_date": "2016-07-15T23:45:13+0000", "news_desk": "Business", "headline": {"print_headline": "New Patents Aim to Delay Generics of Biologics", "main": "Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions"}, "print_page": "1", "snippet": "Six years after the Affordable Care Act cleared the way for biosimilars, as the generic versions of biotechnology drugs are called, progress has been slow....", "_id": "5789758c38f0d829e63ddee8", "slideshow_credits": null, "abstract": "Drug makers Amgen and AbbVie are deploying new patents to delay generic versions of their costly biologics medicines Humira and Enbrel; progress for biosimilars, as generic versions of biotech drugs are called, has been slow in wake of Affordable Care Act."}